AAP
IOVA icon

Arax Advisory Partners’s Iovance Biotherapeutics IOVA Stock Holding History

Arax Advisory Partners’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$325K Buy
78,106
+22,599
+41% +$85.9K ﹤0.01% 1930
2026
Q1 		$195K Buy
55,507
+55,446
+90,895% +$177K 0.01% 1088
2025
Q4 		$167 Sell
61
-1,221
-95% -$2.83K ﹤0.01% 3749
2025
Q3 		$2.78K Buy
+1,282
New +$3.03K ﹤0.01% 3029

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Arax Advisory Partners's IOVA Position: Q2 2026 in Review

Arax Advisory Partners increased its Iovance Biotherapeutics (IOVA) stake by 41% in Q2 2026, buying an estimated $85.9K and bringing the position to 78,106 shares worth $325K. The position accounts for ﹤0.01% of the portfolio, ranked #1930.

Arax Advisory Partners first reported a position in IOVA in Q3 2025 and has held it in 4 quarters since. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Arax Advisory Partners held 78,106 shares of Iovance Biotherapeutics worth $325K as of Q2 2026.
  • Arax Advisory Partners bought 22,599 Iovance Biotherapeutics shares in Q2 2026, an estimated $85.9K.
  • Iovance Biotherapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #1930 holding.
  • Arax Advisory Partners first reported a position in Iovance Biotherapeutics in Q3 2025 and has held it in 4 quarters since.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.